Despite emerging data supporting local ablative therapies in patients with metastatic castration sensitive prostate cancer, there is a paucity of high-quality evidence to guide treatment decisions following the localization of PSA recurrence using medical imaging. The gene discussed is KLK3; the disease is Familial prostate cancer.